Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT07222631RecruitingPhase 1/Phase 2
Study of SB-4826 for advanced solid tumors or lymphomas
This trial tests a new drug, SB-4826, for people with advanced solid tumors or certain types of lymphoma that have not responded to standard treatments. The goal is to see if the drug is safe and effective, either alone or with another drug called rituximab.
La Jolla, CaliforniaAges 18 years+ - NCT07224503Recruiting
Comparing two programs to help brain tumor patients with thinking skills
This study tests two programs—C-SMART and BE Well—to see which one better helps brain tumor patients who struggle with memory, attention, or other thinking skills. You and your caregiver will participate together in this telehealth-based program.
Richmond, VirginiaAges 18 years+ - NCT07229313RecruitingPhase 1
Testing KIVU-107 in advanced solid tumors
This trial tests a new drug, KIVU-107, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug is safe and helps shrink or control the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT07232420RecruitingPhase 1
Study of BL-M24D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07232524RecruitingPhase 1
BL-M24D1 for advanced head and neck and other solid tumors
This study tests a new drug called BL-M24D1 in people with head and neck cancer or other solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and can help shrink tumors.
Chengdu, SichuanAges 18 years+ - NCT07236840Recruiting
Remote neurological exams via smartphone for brain tumor patients
This trial tests if a smartphone app can help patients or caregivers perform a neurological exam at home. It aims to make check-ups easier for people with brain tumors.
Mumbai, MaharashtraAges 5 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT07259590RecruitingPhase 1/Phase 2
GFH375 with cetuximab or chemo for KRAS G12D cancers
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07260305RecruitingPhase 1
Study of KGX101 alone or with Envafolimab for advanced solid tumors
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07260370Recruiting
Studying blood markers in cancer patients on immunotherapy
This study looks at tiny particles (microRNA) and cancer cells in the blood of people with cancer who are getting immunotherapy. It aims to find patterns that might help doctors better understand how the treatment is working.
Taoyuan CityAges 20 years+ - NCT07260591RecruitingPhase 1
VSV-02 for advanced solid tumors that need new options
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
Xinxiang, HenanAges 18 years+ - NCT07269899RecruitingPhase 1
A study of WTX212A with or without radiation for advanced cancer
This trial tests a new drug (WTX212A) alone or with radiation therapy for people with advanced solid tumors. It aims to see if the treatment is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07274852RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Chengdu, SichuanAges 18 years+ - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT07285395RecruitingPhase 1
Study of AT1019 with radiation and immunotherapy for advanced solid tumors
This trial tests a new drug called AT1019 given together with targeted radiation (SBRT) and an immunotherapy drug for people with advanced solid tumors that are already being treated with immunotherapy. It aims to see if this combination can shrink or control tumors better.
Xuzhou, JiangsuAges 18 years+ - NCT07301801RecruitingEarly Phase 1
New scan for detecting and staging certain cancers
This trial tests a new imaging agent (68Ga-FL-031) to see if it can help find and stage tumors in people with small cell lung cancer, breast cancer, nasopharyngeal cancer, or other cancers. The goal is to improve diagnosis and treatment planning.
Wuhan, HubeiAges 18 years+ - NCT07302100Recruiting
Nutrition study for digestive neuroendocrine tumors
This study looks at the nutritional health of people with a type of digestive tumor called a neuroendocrine tumor. It aims to understand how these tumors affect nutrition, which could help doctors improve care.
StrasbourgAges 18–70 - NCT07303387RecruitingPhase 2
Valemetostat for solid tumors with SWI/SNF gene changes
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Villejuif, Val de MarneAges 18 years+ - NCT07304128RecruitingPhase 1
PLB-002 for advanced solid tumors study
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07315828RecruitingPhase 4
ICG imaging to improve surgery for giant cell bone tumors
This trial uses a special dye called indocyanine green (ICG) during surgery to make giant cell bone tumors glow, helping doctors remove them more accurately. It may lead to better surgical outcomes for people with this tumor type.
ShanghaiAges 18–75 - NCT07315841RecruitingPhase 4
Dye Imaging for Tenosynovial Giant Cell Tumor Surgery
This trial tests whether a special dye (Indocyanine Green) used during surgery can help doctors see Tenosynovial Giant Cell Tumors more clearly. It may help make the surgery more precise.
ShanghaiAges 18–75
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.